Obesity candidate CT-388, which Genentech added to Roche’s pipeline with the acquisition of Carmot Therapeutics, is at least not a disappointment, according to new trial data.
https://european-biotechnology.com/wp-content/uploads/2024/06/Roche3.png9101608Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2024-05-19 12:02:002024-07-08 11:14:34Obesity: Roche with first clinical data after US$2.7bn deal